Talent Pool

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Pharma POOL

Dr. Barry Goldstein

Merck Appoints Head of Diabetes, Obesity Development Global pharmaceutical company Merck, Whitehouse Station, N.J., has named Barry Goldstein, M.D., Ph.D., FACP, FACE, VP of diabetes and obesity clinical development. In addition to leading overall development of compounds in Merck’s diabetes and obesity franchise, Dr. Goldstein is also responsible for collaborating with the company’s basic research and global human health organizations to ensure strong alignment globally. He is based at Merck Research Laboratories in Rahway, N.J. Dr. Goldstein spent 16 years on staff at Jefferson Medical College of Thomas Jefferson University, most recently as director of the division of endocrinology, diabetes, and metabolic diseases and professor of medicine, biochemistry, and molecular pharmacology. He received a bachelor’s degree from Cornell University and a medical degree from the University of Rochester School of Medicine. Dr. Paul Korner Former Bayer HealthCare Executive Joins Ferring Pharmaceuticals Privately owned Ferring Pharmaceuticals, Parsippany, N.J., has named Paul Korner, M.D., MBA, VP, medical affairs, with responsibility for the company’s infertility, orthopedics, urology, and gastroenterology therapeutic areas, as well as product safety. Dr. Korner, a board-certified obstetrician and gynecologist, was previously VP of medical affairs, women’s healthcare, at Bayer HealthCare Pharmaceuticals. He received an MBA from the Michael J. Coles College of Business at Kennesaw State University and an M.D. from Loyola University Chicago Stritch School of Medicine. Dr. Gregory Landes Takeda San Francisco Hires VP of Antibody Research Takeda San Francisco, a U.S. subsidiary of Japan’s Takeda Pharmaceutical Co. Ltd. that is focused on therapeutic antibody research, has appointed Gregory Landes, Ph.D., VP of antibody research. Dr. Landes is responsible for directing the discovery and preclinical development of therapeutic antibodies at Takeda’s antibody IND engine and center of excellence for biologics. Dr. Landes has more than 25 years of experience in the biopharmaceutical industry and has held executive positions with companies such as Lexicon Pharmaceuticals, Abgenix, and Genzyme. He received a B.A. in chemistry and a Ph.D. in biochemistry from the University of Kansas. Daniel McIntyre New Communications VP at Wyeth Wyeth, Madison, N.J., has named Daniel McIntyre VP, corporate communications, responsible for global internal and external communications for the corporation and its three major divisions: pharmaceuticals, consumer healthcare, and animal health. Most recently, Mr. McIntyre was managing director of the healthcare practice of Fleishman-Hillard International Communications. He is an honors graduate of Seton Hall University and holds an MPA from Rutgers University. Biopharmaceutical POOL Frederick Driscoll Genelabs Taps Financial Chief as CEO Genelabs Technologies, a Redwood City, Calif.-based biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases, has promoted Frederick Driscoll to president and CEO. Mr. Driscoll most recently served as Genelabs’ chief financial officer and has been sharing CEO responsibilities with Executive Chairman Irene Chow, Ph.D. Nicholas Hart Emisphere Appoints Strategy VP Emisphere Technologies, Cedar Knolls, N.J., has named Nicholas Hart VP of strategy and development, with responsibility for the planning and commercial development aspects of Eligen drug-delivery technology. Mr. Hart was most recently leader of the contraception therapy area at Organon. He is a graduate of the U.S. Military Academy at West Point and received an MBA in finance and international business from New York University’s Leonard N. Stern School of Business. Dr. Michael LaBarre Dr. Patrick O’Connor Halozyme Strengthens Clinical Leadership Halozyme Therapeutics, a San Diego-based biopharmaceutical company, has appointed Michael LaBarre, Ph.D., VP, product development. Dr. LaBarre most recently served as VP of product development at Paramount BioSciences. He received a B.S. in chemistry from Southampton College and a Ph.D. in bioinorganic chemistry from the University of Arizona. Patrick O’Connor, Ph.D., has been named VP, research, responsible for leading Halozyme’s multiple biology and chemistry research programs. Dr. O’Connor was previously senior VP and chief scientific officer at Ardea Biosciences. He received a B.Sc. in pharmacology from the University of Bradford and a Ph.D. in experimental oncology therapeutics from the University of Manchester, both based in the United Kingdom. Isabelle Mercier Dr. Claire Thom Millennium Expands Leadership Millennium: The Takeda Oncology Company, a Cambridge, Mass.-based biopharmaceutical company focused on cancer therapies, has added two executives to its leadership team. Isabelle Mercier has joined Millennium as VP, marketing, for the company’s commercial organization. Ms. Mercier most recently served as VP of Taxotere marketing at Sanofi-Aventis. She earned dual B.S. degrees in biochemistry and clinical biology and an advanced degree in biotechnologies from Université Catholique de Lyon in France, as well as a B.S. in genetic and cellular biology from l’Université Lyon I. Claire Thom, Pharm.D., has been named senior VP, portfolio management, for the company’s oncology portfolio. Previously, Dr. Thom was responsible for the oversight and implementation of global therapeutic area strategies for the oncology, urology, and gynecology franchises of Takeda Pharmaceutical Co. Ltd. in Japan. She received a bachelor of pharmacy degree with high honors and a doctorate of pharmacy with honors from the University of Illinois at Chicago. Sanj Patel Former Genzyme VP Assumes Top Spot at Synageva Synageva BioPharma, a biopharmaceutical company focused on multiple therapeutic areas, including oncology and autoimmune and genetic diseases, has named Sanj Patel as president and CEO. The appointment coincides with the opening of Synageva’s corporate headquarters in Waltham, Mass. Synageva maintains research and production operations in the greater Atlanta area, where the company was originally founded under the name of Avigenics. Mr. Patel joins Synageva after nine years at Genzyme, where he most recently was head of U.S. sales, marketing, and commercial operations for the Genzyme Therapeutics business. He obtained his B.Sc. with honors in pure and applied biotechnology from London South Bank University and successfully completed his doctorate program in clinical pharmacology from King’s College and The Wellcome Foundation. He also received a postgraduate management and business degree and training from Ealing College in London. Specialty POOL Jack Britts Merz Pharmaceuticals Chooses CEO Merz Pharmaceuticals, Greensboro, N.C., has named Jack Britts president and CEO. In this role, Mr. Britts is overseeing further growth of Merz’s current medical dermatology business and the establishment of two new business units to support the company’s robust product pipeline in aesthetics and neurology. He joins Merz after eight years with Sepracor, where he most recently served as group VP in charge of commercial operations. Merz Pharmaceuticals, a subsidiary of privately held German pharmaceutical company Merz GmbH & Co., is responsible for the North American introduction of neurologic and dermatologic products developed within the global Merz organization. Maria Cantor Ariad Selects Head of Communications Ariad Pharmaceuticals, Cambridge, Mass., has appointed Maria Cantor to the newly created position of VP, corporate communications and investor relations. Ms. Cantor most recently was a senior director of corporate communications at Genzyme. She received a B.S. from Emerson College and an M.S. in communications management from Syracuse University. Ariad discovers and develops medicines to treat cancer by regulating cell signaling with small molecules. Dr. Geert Cauwenbergh RHEI Appoints CEO Geert Cauwenbergh, Ph.D., has joined RHEI Pharmaceuticals as CEO, succeeding Joos Horsten, who recently passed away. RHEI Pharmaceuticals, New Haven, Conn., is a venture-backed specialty pharmaceutical company that acquires, licenses, develops, and commercializes proprietary drug therapies based upon the unmet needs of the emerging pharmaceuticals market in China. Since August 2008, Dr. Cauwenbergh has been assisting RHEI Pharmaceuticals in providing the necessary leadership to continue the company’s development. Before that, in February 2008, he founded Phases123 LLC, a company focused on identifying high-potential healthcare technology platforms and emerging healthcare companies. Dr. Cauwenbergh received a Ph.D. in medical sciences from Katholieke Universiteit Leuven in The Netherlands, where he also completed his master’s and undergraduate work. Dr. Christopher Hensby Quinnova Appoints R&D Executive Quinnova Pharmaceuticals, Newtown, Pa., a specialty pharmaceutical company focused on developing products based on topical drug delivery platforms, has named Christopher Hensby, Ph.D., senior VP, research and development. He previously was VP of R&D and regulatory affairs for Ivrea Pharmaceuticals. He received a B.Sc. in pharmacology from King’s College in London and a Ph.D. from The University of Edinburgh. Eric Loukas Milestone Biosciences Appoints CEO Milestone Biosciences, Altamonte Springs, Fla., a privately held specialty biotechnology company focused on niche oncology products, has named Eric Loukas to succeed company cofounder Frank Jacobucci as CEO. Mr. Jacobucci remains president and chief operating officer of Milestone. Before joining Milestone, Mr. Loukas was executive VP, chief operating officer, and general counsel and corporate secretary of MGI Pharma. He received a B.A. in experimental psychology from The State University of New York at Albany, an M.S. in pharmacology from Rutgers University, and a J.D. from The John Marshall Law School. Joseph Merkert Daniel Schneider Somaxon Expands Sales Leadership Somaxon Pharmaceuticals has appointed two executives to newly created sales VP positions as the specialty company prepares for the potential commercialization of Silenor, which is awaiting FDA approval for the treatment of insomnia. Somaxon, San Diego, is focused on the in-licensing and development of product candidates for treating psychiatric and neurological diseases and disorders. Joseph Merkert has joined Somaxon as VP of sales operations and managed care. Mr. Merkert was previously VP of commercial operations at Verus Pharmaceuticals. Daniel Schneider has been named VP of sales. Most recently, Mr. Schneider was area VP of sales at Sepracor. Emerging POOL Patricia Andrews Incyte Taps Former Pfizer VP as Chief Commercial Officer Incyte, Wilmington, Del., has named Patricia Andrews to the newly created position of executive VP and chief commercial officer. Ms. Andrews joins Incyte after 17 years with Pfizer, where she most recently served as VP and general manager of the U.S. oncology business unit. Incyte is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs in oncology, inflammation, and diabetes, among other conditions. Dr. Thomas Hughes Zafgen Taps Novartis Institutes VP as CEO Zafgen, Cambridge, Mass., a private venture-backed biopharmaceutical company focused on developing novel obesity therapeutics, has named Thomas Hughes, Ph.D., as its first permanent CEO. Dr. Hughes succeeds Zafgen board member Kevin Starr, partner at Third Rock Ventures, who had been serving as interim CEO. The move comes as Zafgen advances its lead molecules with the goal of entering clinical testing in 2009. Dr. Hughes was previously VP and global head, cardiovascular and metabolism disease area, at the Novartis Institutes for BioMedical Research. He received a B.A. in biology from Franklin and Marshall College, an M.S. in zoology from Virginia Polytechnic Institute & State University, and a Ph.D. in nutritional biochemistry from Tufts University. Agency POOL Garrett Allen Megan Blickley Chris Cummings Kim Fantine Mary Jo Furnbach Thomas Groves GSW Announces Several Staff Additions Full-service agency GSW Worldwide, an inVentiv Health company, has announced a number of new hires at its headquarters in Columbus, Ohio, and its offices in New York and Newtown, Pa. The New York office has appointed Garrett Allen senior copywriter. Mr. Allen previously served as senior copywriter for Concentric Pharma Advertising. He received a master’s degree from Georgetown University’s Edmund A. Walsh School of Foreign Service. Megan Blickley has joined the Newtown office as account executive. Ms. Blickley previously was associate account executive at Garfield Group. She holds a bachelor’s degree from Temple University. In Columbus, Chris Cummings has been named multimedia designer. Mr. Cummings most recently was senior designer at Mills James. He earned a bachelor’s degree from Columbus College of Art and Design. Kim Fantine has joined the Columbus office as VP, account director. Previously, Ms. Fantine served as program manager for Abbott Nutrition. She has a bachelor’s degree from Indiana University. In New York, Mary Jo Furnbach has been named VP, associate creative director. Ms. Furnbach most recently held the same position at DraftFCB. She received a master’s degree from Eastern University. Thomas Groves has joined the Columbus office as executive VP, director of strategic planning, responsible for leading planning and development capabilities across all GSW locations. Mr. Groves was previously executive VP, director of account planning, at Ogilvy Healthworld. Mark Bennett Paul Laland Emily Poe Scott Santiamo Jessica Volchok WeissComm Expands Staff Independent healthcare communications agency WeissComm Partners has announced several new hires at four of its U.S. locations. Mark Bennett has been named senior associate in the company’s New York office. Mr. Bennett was previously senior manager, corporate communications, at Bayer HealthCare Pharmaceuticals. He holds a B.A. in communications from Marist College. Paul Laland has joined WeissComm’s main office in San Francisco as executive VP. Mr. Laland has nearly 25 years of experience in pharmaceutical corporate and product communications, most recently as VP of corporate communications for Novacea. At WeissComm’s office in Philadelphia, Emily Poe has been hired as senior associate. Ms. Poe was previously a VP at Vox Medica. She received a B.S. in biology from Cornell University. Scott Santiamo has joined the New York office as senior associate from MedImmune, where he served as a communications consultant. He obtained a B.A. in communications from Iona College. In Los Angeles, Jessica Volchok has been appointed senior associate. Ms. Volchok was part of the medical devices and diagnostics practice at FischerHealth, a Porter Novelli company. She earned a bachelor’s degree in communications from California State University, Fullerton. Ann Bledsoe Leslie Bowe Lisa Kaufman Christie Miller Centron Promotes and Adds Staff Centron, New York, a HealthSTAR Communications company and full-service medical communications agency, has announced one addition and several promotions to its staff. Centron is a full-service medical communications agency offering senior-level strategic expertise across a range of therapeutic areas. Ann Bledsoe has been promoted to managing editor from medical editor. Leslie Bowe has been promoted to senior account executive from account executive. Lisa Kaufman has advanced to account group supervisor at Centron. Previously, she was an account supervisor. Christie Miller has joined Centron as account supervisor. Previously, Ms. Miller was grant director at Impact Communications. John Fleetwood Todd Martin AbelsonTaylor Adds, Promotes Independent healthcare advertising agency AbelsonTaylor, Chicago, has hired John Fleetwood as senior interactive developer. Mr. Fleetwood most recently was new media developer at b|media. AbelsonTaylor also has promoted Todd Martin to art director from associate art director. In this role, Mr. Martin is working on products in various therapeutic specialties including diabetes, oncology, and women’s health. He received a B.S. in advertising from Ball State University. Greg Kirsch Intouch Solutions Selects Creative Services VP Intouch Solutions, Overland Park, Kan., a privately held digital marketing communications agency servicing the pharmaceutical industry, has appointed Greg Kirsch VP of creative and development services. Mr. Kirsch most recently served as VP of creative services, training, and development at PlattForm Advertising. He earned a B.S. in marketing from Indiana University. Andrew le Blanc Cadient Names Creative Director Cadient Group, West Conshohocken, Pa., an independent interactive marketing agency serving the healthcare industry, has appointed Andrew le Blanc creative director. He received a B.A. in advertising from the University of Massachusetts Amherst. Sean Pirtle Richard Yale Ignite Health Expands Irvine Staff Ignite Health, an inVentiv Health company that specializes in patient-centered, technology-driven medical advertising, has announced two appointments to its Irvine, Calif., office. Sean Pirtle has been named producer. Mr. Pirtle previously was account supervisor, senior producer, at Interactivate. He holds a master’s degree from Chapman University. Richard Yale has joined Ignite Health as Web developer from the same position at The Dot Fulfillment. He received a bachelor’s degree from University of California, Irvine. Marc Weiner CommonHealth Promotes Managing Partner CommonHealth, Parsippany, N.J., has promoted Marc Weiner to managing partner of the organization, with responsibility for overseeing management of CommonHealth’s EvoLogue consumer, Qi digital, and Conectics media planning and placement service offerings. Also in his expanded position, Mr. Weiner is responsible for evolving, advancing, and integrating CommonHealth’s direct-to-consumer, relationship marketing, and interactive businesses. He continues to serve as president of the Qi and Conectics groups. CRO POOL Peter Gonze Averion Selects Business Development VP Full-service international clinical research organization Averion International has appointed Peter Gonze executive VP of global business development. Mr. Gonze has more than 35 years of pharmaceutical sales, marketing, and development experience, most recently as chief operating officer at Unither Pharmaceuticals. Averion, Southborough, Mass., specializes in oncology, cardiovascular diseases, and medical devices. Evette Riegel Beardsworth Makes Promotion Beardsworth Consulting Group, Flemington, N.J., has promoted Evette Riegel, R.N., to project director in clinical operations, giving her a lead role in integrating the contract research organization’s global services and oncology operations. Ms. Riegel, who joined Beardsworth in 2006, has 12 years of experience in clinical study and project management, running trials in the United States and globally. Dr. Ross Tonkens MDS Pharma Appoints Medical Affairs VP Ross Tonkens, M.D., has joined MDS Pharma Services, King of Prussia, Pa., as VP, medical affairs. Dr. Tonkens provides medical oversight for MDS Pharma’s Phase IIa clinical research activities and directs the medical and clinical activities of its development and regulatory services line of business. In addition, he serves as the 2008 Chair of the Ethics & Clinical Practice Committee of the Association of Clinical Research Organizations (ACRO). Dr. Tonkens previously was chief medical officer at Regado Biosciences. He is a graduate of Yale University’s Yale College and Yale Medical School. Media POOL Erich Burnett Bob Feigenbaum Brandon Glenn Ken Krizner Morgan Lewis Jr. Advanstar Unveils New Editorial Staff at Medical Economics Advanstar Communications has announced its new Cleveland-based Medical Economics editorial staff. Erich Burnett has joined Medical Economics as editor-in-chief. Mr. Burnett spent the last 12 years at Village Voice Media, where he most recently served as the fourth-ranking editorial officer. He holds a B.S. in communication from Ohio University. Bob Feigenbaum has been named articles editor. He was previously editor-in-chief of Physician’s Management. He received a master’s degree in journalism from Boston University. Brandon Glenn has been appointed a senior editor of Medical Economics. He most recently served as a staff reporter at Crain’s Chicago Business. He earned a master’s degree in journalism from Northwestern University’s Medill School of Journalism. Ken Krizner, has been named managing editor. Mr. Krizner has more than 20 years of experience writing and editing for newspapers and business magazines. He graduated from Kent State University with a degree in journalism. Morgan Lewis Jr. has joined Medical Economics as a senior editor, from the same position at Inside Business. Mr. Lewis is a graduate of Miami University of Ohio with a degree in journalism. Medical Education POOL Mary Anderson Dr. Michael Melucci Michael Pucci Dr. Tara Ruest Dr. Jennifer Steeber HLS Makes Promotions and Additions HLS, CommonHealth’s medical-education unit, has announced a number of promotions and one new hire. Mary Anderson has been promoted to president, assuming primary responsibility for HLS. Additionally, Ms. Anderson continues to manage the HLS leadership committee as well as overseeing all client activity. She also serves on the healthcare agency’s executive committee. Michael Melucci, Ph.D., has been promoted to senior VP, account group supervisor, from VP, account director. A 12-year veteran of HLS, Dr. Melucci manages strategy and business development for a variety of clients. Michael Pucci joins HLS as a medical director, with responsibility for providing medical expertise to clients and overseeing the development of medical content for publications. Most recently, Mr. Pucci was a scientific supervisor at Ogilvy Healthworld. Tara Ruest, Ph.D., has been promoted to senior medical director from medical director. In this position, she is responsible for providing medical expertise and directing the development of medical content for live meetings and publications. Jennifer Steeber, Ph.D., has been promoted to medical director from associate medical director, with responsibility for guiding the development of medical content and providing medical expertis. Service POOL Alayne Green Scientific Voice Names Operations VP Alayne Green has joined Scientific Voice as a VP of operations. She will share her time between the company’s two offices in Chicago and Blue Bell, Pa. Ms. Green has more than 15 years of experience in speaker bureau and bureau-related services. Most recently, she served as senior operational director at Wyeth. Scientific Voice, a member of the Publicis Healthcare Communications Group, provides speaker bureau programming to the health-sciences industry. Terrell Herring inVentiv Health Promotes Chief Operating Officer to President inVentiv Health, a Somerset, N.J.-based provider of commercialization services to the global pharmaceutical and healthcare industries, has named Chief Operating Officer Terrell Herring to the additional role of president. In this expanded capacity, Mr. Herring oversees the four major divisions of inVentiv Health: inVentiv Clinical, inVentiv Commercial, inVentiv Communications, and inVentiv Patient Outcomes. In addition to chief operating officer, Mr. Herring previously served as CEO of inVentiv Commercial and inVentiv Patient Outcomes. Dr. Sharon Huss New Business Development Director at SOS Science Oriented Solutions (SOS), Atlanta, a full-service contract medical organization and member of the Publicis Healthcare Communications Group (PHCG), has brought Sharon Huss, M.D., on board as director of business development. Dr. Huss is responsible for developing and implementing initiatives to expand and foster client relationships, as well as exploring new business opportunities. Most recently, Dr. Huss was a medical information specialist with Cegedim Dendrite. Bryan Koslow Q Pharma Selects Marketing Chief Q Pharma, a Morristown, N.J.-based provider of FDA regulatory and compliance solutions, has appointed Bryan Koslow as VP of sales and marketing. Mr. Koslow’s most recently was VP of sales and business development at Sparta Systems. Mr. Koslow received bachelor’s degrees in finance and computer information systems from Hofstra University. Additionally, he received an MBA in accounting from Monmouth University. Scott Lubeck Wolters Kluwer Health Adds Executive Wolters Kluwer Health has appointed Scott Lubeck VP, technology, of its professional and education unit based in Philadelphia. Mr. Lubeck was previously VP/general manager at Newsstand. He earned an A.B. degree from Brown University and an M.A. from the University of Texas. Wolters Kluwer Health, Conshohocken, Pa., a division of Wolters Kluwer, provides information and business intelligence to the pharmaceutical industry. Dr. David Shearer ICTS Names Executive to Oversee Medical Functions David Shearer, M.D., has joined full-service patient enrollment firm Integrated Clinical Trial Services (ICTS), Raleigh, N.C., as chief medical officer and VP of clinical operations. Dr. Shearer was most recently medical director of diabetes at MannKind. Timothy Tyson Aptuit Appoints Acting CEO Aptuit has appointed 30-year pharmaceutical industry veteran Timothy (Tim) Tyson executive chairman and acting CEO. Mr. Tyson most recently served as chief operating officer, president, and CEO of Valeant Pharmaceuticals International. Aptuit, Greenwich, Conn., conducts research, development, and manufacturing on a contract basis. Deena Wegner Drug Safety Alliance Names Business Development VP Drug Safety Alliance (DSA), a Research Triangle Park, N.C.-based provider of pharmaceutical safety and pharmacovigilance services, has appointed Deena Wegner VP, business development and strategy. She received a B.S. in biology from Tulane. F Send your personnel announcements to feedback@pharmavoice.com. STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION 1. Publication title: PharmaVOICE 2. Publication no.: ISSN: 1932-961X 3. Filing date: September 28, 2008 4. Issue frequency: published monthly except August and December 5. No. of issues published annually: 10 6. Annual subscription price: US: $190. Non-US: $360. 7. Complete mailing address of known office of publication: PharmaLinx LLC, P.O. Box 327, Titusville, NJ 08560 8. Complete mailing address of headquarters or general business office of publisher: PharmaLinx LLC, P.O. Box 327, Titusville, NJ 08560 9. Full names and complete mailing addresses of publisher, editor, and managing editor: Lisa Banket, P.O. Box 327, Titusville, NJ 08560, Taren Grom, P.O. Box 327, Titusville, NJ 08560, and Denise Myshko, P.O. Box 327, Titusville, NJ 08560 10. Owner: Lisa Banket, Taren Grom, and Marah Walsh 11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: (none) 13. Publication title: PharmaVOICE 14. Issue date for circulation data below: September 2008 15. Extent and nature of circulation (avg. no. copies each issue during preceeding 12 months and actual no. copies of single issue published nearest to filing date, respectively). Total no. copies – 19,030 and 19,200. Individual paid/requested mail subscriptions stated on Form 3541: 17,130 and 17,094. Sales through dealers and carriers, street vendors, counter sales, and other paid or requested distribution outside USPS: 36 and 34. Total paid and/or requested circulation: 17,166and 17,128. Nonrequested copies stated on Form 3541: 680 and 476. Nonrequested copies distributed outside the mail: 692 and 877. Total nonrequested distribution: 1,538 and 1,505. Total distribution: 18,704 and 18,633. Copies not distributed: 326 and 567. Total: 19,030 and 19,200. Percent paid and/or requested circulation: 91.78 and 91.92. 16. This statement of ownership will be printed in the November/December 2008 issue of this publication. 17. I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties). (Signed) Marah Walsh, Founding Partner

Posted in:

Post a Comment

You must be logged in to post a Comment.